Moreover, CVT-313 (a selective inhibitor of Cdk2) treatment blocked the SLCO4A1-AS1-induced elevation of c-Myc and p-62 c-Myc (Fig. 6h) in CRC cells. This evidence concerns the gene CDK2 and colorectal carcinoma.